Comparison of Denosumab Alone Versus Teriparatide Followed by Denosumab to Prevent Osteoporotic Fractures in Patients with New Fractures

What this Trial Is About

Researchers are studying patients with osteoporotic fractures to find better prevention and treatment methods for refractures. This project involves registering patients for follow-up studies to collect epidemiological data and conducting prospective treatment studies. It aims to explore effective treatment strategies through randomized controlled trials and to develop warning models using biomarkers and new imaging technologies to predict osteoporotic refractures. Participants receive either denosumab alone or a sequential treatment starting with teriparatide followed by denosumab. Denosumab is given as a 60mg subcutaneous injection every six months for 24 months. Teriparatide is administered as a daily 20ug subcutaneous injection for either 6 or 12 months before switching to denosumab, which continues until the 24th month. These treatment plans are part of a multicenter randomized controlled trial. During the study, participants will be monitored for new vertebral fractures and changes in bone mineral density BMD at the lumbar spine, total hip, and femoral neck over 12 and 24 months. Blood tests will measure biomarkers related to bone turnover at several time points. Researchers will also track patients adherence to treatment and assess cost-effectiveness. Follow-up includes evaluation of new fractures at various sites and safety monitoring throughout the 24-month treatment period.

Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture